近日，无锡途深智合人工智能科技有限公司及其子公司上海途深生物科技有限责任公司（以下简称“途深智合”）宣布成功完成数百万元的天使轮融资，此次投资由诚美资本领衔。途深智合成立于2023年，专注于利用人工智能技术进行蛋白质设计和优化，致力于为合成生物学领域提供创新的解决方案和新产品。
本轮融资资金将主要用于实验室的建设和团队的扩展，以加快公司在AI蛋白质设计与优化技术方面的研发进程。途深智合的愿景是成为该领域的领军企业，通过技术创新推动生物科技行业的进步。
途深智合的成功融资标志着投资者对于人工智能在生命科学领域的应用前景充满信心，同时也预示着合成生物学和生物制造行业正迎来一股新的发展浪潮。随着资金和人才的注入，途深智合有望在未来的市场竞争中占据有利位置，为社会带来更多创新的生物技术和产品。
英文标题：Tushen BioTech Secures Angel Round Financing of Several Million to Advance AI Protein Design and Optimization Technologies
英文关键词：AI protein design, biotechnology, funding
英文新闻内容：
Recently, Tushen Intelligent Integration AI Technology Co., Ltd. and its subsidiary Shanghai Tushen Biotech Co., Ltd. (collectively referred to as “Tushen BioTech”) announced the successful completion of several million in angel round financing, led by Chengmei Capital. Founded in 2023, Tushen BioTech is dedicated to using artificial intelligence to design and optimize proteins, providing innovative solutions and products for the field of synthetic biology.
The funds raised in this round will primarily be used for the construction of laboratories and the expansion of the team, accelerating the company’s research and development progress in AI protein design and optimization technologies. Tushen BioTech envisions becoming a leading enterprise in the field, driving the advancement of the biotechnology industry through technological innovation.
The successful financing of Tushen BioTech marks investor confidence in the application prospects of artificial intelligence in the life sciences, and also signals a new wave of development for the synthetic biology and biomanufacturing industries. With the injection of capital and talent, Tushen BioTech is poised to gain a favorable position in the competitive landscape of the future, bringing more innovative biotechnologies and products to society.
【来源】https://36kr.com/p/2686282258132355
Views: 2